Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

The Year In Preview

If you are not yet a Scrip subscriber, please click on the button below to request your free trial.
Request Your Free Trial
A stymied Japanese research-based sector?
Signs point to yes.
"I expect early 2017 to be marked by uncertainty for the research-based sector until the final form of sweeping government reimbursement pricing reforms and the new annual price cut system are finalized."
– Ian Haydock, Editor-in-Chief, Pharma APAC

Read More > 2017 Preview: Give And Take Marks Mixed Japan, Korea Outlook

Q1 uncertainty for India's big pharma?
Most likely.
"I expect early 2017 to be jittery for top Indian firms until there is clarity on new US President Donald Trump's policies, given the large contribution of the US market to their revenues."
– Anju Ghangurde, Deputy Editor, Pharma APAC

Read More > India Pharma 2017: 3Cs And D (Disruption)?

A shake up of the pricing landscape in China?
You may rely on it.
"2017 promises an expanded national reimbursement drug list that will increase access to new drugs and benefit manufacturers, updated healthcare reform models, and an anticorruption crackdown that will put pricing under pressure."
– Brian Yang, Senior Editor, Pharma APAC

Read More > 2017 Preview: Fresh Concerns And New Hopes In China